Please assess the completion status of the following clinical trial:

Trial Title: Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes Mellitus type 2~2. HbA1c ≥ 5.5% and ≤ 7.0%~3. Treatment with Metformin (daily dose 500 - 3000 mg monotherapy, the past 3 months)~4. Age 30 - 65 years~Exclusion Criteria:~1. Pre-treatment with PPAR gamma agonists or DPP IV inhibitors or GLP-1 analogues within the last three months~2. History of type 1 Diabetes Mellitus~3. No full legal mental and physical ability to give informed consent~4. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 90 mmHg)~5. Anamnestic acute and chronic infections~6. Inflammatory bowel disease and/or diabetic gastroparesis~7. Anamnestic history of epilepsy~8. Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures~9. History of severe or multiple allergies~10. Treatment with any other investigational drug within 3 months before trial entry~11. Progressive fatal disease~12. History of drug or alcohol abuse in the past 2 years~13. Liver disease with ASAT or ALAT above 3 times the upper normal limit~14. Serum potassium \> 5.5 mmol/L~15. Moderate to Severe Kidney disease with a GFR ≤ 60 ml/min~16. Pregnancy or breast feeding~17. Sexually active woman of childbearing potential not practicing a highly effective method of birth control as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomised partner~18. Have had more than one unexplained episode of severe hypoglycaemia (defined as requiring assistance of another person due to disabling hypoglycaemia) within 6 months prior to screening visit~19. History of dehydration, diabetic precoma, diabetic ketoacidosis or diabetic gastroparesis~20. Acute (within the previous 2 days) or scheduled investigation with iodine containing radiopaque material~21. Acute myocardial infarction, open heart surgery or cerebral event (stroke/TIA) within the previous 6 months~22. Anamnestic uncontrolled unstable angina pectoris, pericarditis, myocarditis, endocarditis, haemodynamic relevant aortic stenosis, aortic aneurysma or heart insufficiency NYHA III or IV~23. Anamnestic recent pulmonary embolism or pulmonary insufficiency~24. Smoking within the last 6 months (\> 1 cigarette/day)~25. Planned change in antidiabetic, lipid lowering or blood pressure medication

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: NO_INTERVENTION): Patients taking Metformin at individual dose
- Metformin and Liraglutide (Type: EXPERIMENTAL): Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).